Millions of consumers reaching for over-the-counter cold and flu relief this winter may be purchasing products containing phenylephrine, a common nasal decongestant that regulatory experts have determined is ineffective when taken orally. Despite its widespread inclusion in popular medicine, recent findings from the U.S. Food and Drug Administration (FDA) have confirmed that the oral version of the drug does not provide the relief it claims to offer for nasal congestion.
The FDA’s Nonprescription Drugs Advisory Committee held a public meeting in September 2023, where independent experts reviewed the latest clinical data. The committee unanimously concluded that the current evidence does not support the efficacy of oral phenylephrine as a decongestant. This regulatory shift marks a significant departure from decades of established practice in the pharmaceutical industry, raising questions about how such products remained on pharmacy shelves for years despite insufficient evidence of their performance.
Understanding the FDA’s Findings on Oral Phenylephrine
Phenylephrine has been a staple in the medicine cabinet for decades, often appearing as the primary “PE” designation on the packaging of multi-symptom cold and flu tablets. However, the FDA clarified in late 2023 that while the drug is safe, it is essentially ineffective when swallowed. The issue lies in how the human body metabolizes the ingredient. When ingested orally, phenylephrine is broken down extensively in the gut and liver before it can reach the bloodstream in significant enough concentrations to shrink swollen nasal passages.
This is a distinct contrast to phenylephrine administered via nasal sprays, which remains an effective treatment because it is applied directly to the site of the congestion. The FDA’s review highlighted that the body’s digestive process renders the oral pill version nearly useless for the intended purpose of clearing blocked sinuses. Following the advisory committee’s decision, the FDA issued a formal proposal to remove oral phenylephrine from the list of approved active ingredients for over-the-counter nasal decongestants.
Why These Products Remained on the Market
The presence of ineffective medication on retail shelves for years is largely attributed to the history of FDA oversight. Many of these products were approved under a “Generally Recognized as Safe and Effective” (GRASE) designation, a regulatory framework established in the 1970s. Over time, as drug manufacturing standards evolved and more rigorous clinical trials became the industry benchmark, the data supporting oral phenylephrine began to appear outdated.
According to the FDA’s official summary of the 2023 advisory meeting, the original studies that led to the drug’s approval were conducted decades ago and did not meet modern standards for clinical efficacy. The agency noted that it often takes time for new, high-quality data to challenge long-standing regulatory approvals, particularly for products that are widely considered safe, even if their therapeutic benefit is negligible.
What Consumers Should Know This Winter
For those seeking relief from seasonal congestion, the shift in regulatory status means that checking the “Active Ingredients” label is more important than ever. If a cold or flu tablet lists phenylephrine as the sole decongestant, it may not offer the relief consumers expect. The FDA maintains that oral phenylephrine does not pose a safety risk, but it simply fails to perform its primary job. Consumers are encouraged to look for alternatives, such as pseudoephedrine—which is often kept behind the pharmacy counter due to its potential for misuse in illegal drug manufacturing—or to consult with a pharmacist regarding other effective treatments.
The regulatory process is ongoing. Following the advisory committee’s recommendation, the FDA moved to issue a proposed order to reclassify oral phenylephrine. As of early 2024, the agency has been soliciting public comments and working toward a final regulatory decision that would effectively force manufacturers to reformulate their products. Until then, many products containing the ingredient remain available for purchase, as the FDA’s proposed order does not constitute an immediate ban.
Key Considerations for Symptom Management
The following points summarize the current regulatory and medical understanding of oral phenylephrine usage:
- Efficacy: Independent scientific reviews have found that oral phenylephrine is no more effective than a placebo for treating nasal congestion.
- Safety: The ingredient is not considered harmful to the general population; the primary concern is its lack of medical benefit.
- Labeling: Consumers are advised to check the active ingredient list on cold and flu medicine to identify whether phenylephrine is the decongestant used.
- Alternatives: Pharmacists remain the best resource for identifying proven, evidence-based alternatives for sinus and nasal congestion.
The next steps in this process involve the finalization of the FDA’s proposed order. The agency continues to monitor the market and provide updates on its website as it moves toward removing the drug from the list of approved non-prescription treatments. Readers are encouraged to check the official FDA Drug Safety and Availability portal for the most recent regulatory announcements and guidance on medication efficacy.
If you have questions about specific medications in your home, consult your local pharmacist or primary care physician for guidance. Please share this information with friends and family to help them make informed choices during the current cold and flu season.
Worth a look